Compulsory Licensing: A Study with Reference to India’s First Pharmaceutical Compulsory License Case of Natco vs. Bayer
20 Pages Posted: 15 Sep 2012
Date Written: September 14, 2012
Abstract
Recent judgment by India on compulsory License of Bater's Patented cancer drug Nexavar to Indian generic company Natco is potentially a game changer for whole pharmaceutical industry. This paper examines if India is TRIPS compliant while use the TRIPS flexibility of CL.
Keywords: Natco, Compulsory License, TRIPS, India, Bayer, Nexavar, Cipla, flexibility, patent, pharmaceutical
JEL Classification: K11, K33, K41
Suggested Citation: Suggested Citation
Mathur, Charu, Compulsory Licensing: A Study with Reference to India’s First Pharmaceutical Compulsory License Case of Natco vs. Bayer (September 14, 2012). Available at SSRN: https://ssrn.com/abstract=2146821 or http://dx.doi.org/10.2139/ssrn.2146821
Do you have negative results from your research you’d like to share?
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.